DOCSLIB.ORG

212994 Serdexmethylphenidate and Dexmethylphenidate Unireview Prea

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
212994 Serdexmethylphenidate and Dexmethylphenidate Unireview Prea NDA/BLA Multi-disciplinary Review and Evaluation: NDA 212994 Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules, for oral use NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NME NDA Application Number(s) NDA 212994 Priority or Standard Standard Submit Date(s) 03/02/2020 Received Date(s) 03/02/2020 PDUFA Goal Date 03/02/2021 Division/Office Division of Psychiatry (DP)/Office of Neuroscience Review Completion Date 03/02/2021 Established/Proper Name Serdexmethylphenidate chloride (SDX Cl) & Dexmethylphenidate hydrochloride (d-MPH HCL) (Proposed) Trade Name Azstarys Pharmacologic Class Stimulant (Drugs for Minimal Brain Dysfunction) Code name N/A Applicant Commave Therapeutics SA Dosage form 26.1/5.2 mg, 39.2/7.8 mg, 52.3/10.4 mg (expressed as SDX/d- MPH free base) capsules (for reference, in parts of this review and others, sometimes the doses are also expressed in chloride salt form as 28/6 mg; 42/9 mg; and 56/12 mg respectively) Applicant proposed Dosing 26.1 mg/5.2 mg once daily in the morning. The dose may be Regimen increased weekly in increments of 13.1 mg/2.6 mg per day to a maximum of 52.3 mg/10.4 mg Applicant Proposed Treatment of Attention Deficit-Hyperactivity Disorder (ADHD) Indication(s)/Population(s) in patients ages 6 years and older Applicant Proposed 406506008 SNOMED CT Indication Disease Term for each Proposed Indication Recommendation on Approval Regulatory Action Recommended Treatment of ADHD in patients ages 6 to 12 years Indication(s)/Population(s) (if applicable) Recommended SNOMED 406506008 CT Indication Disease Term for each Indication (if applicable) Recommended Dosing 26.1/5.2 mg once daily in the morning, may be increased Regimen weekly in increments of 13.1/2.6 mg per day with a maximum of 52.3/10.4 mg 1 Version date: July 7, 2019 Reference ID: 4754756 NDA/BLA Multi-disciplinary Review and Evaluation: NDA 212994 Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules, for oral use Table of Contents Table of Tables ................................................................................................................................ 5 Table of Figures ............................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ................................................................ 8 Glossary ......................................................................................................................................... 12 1 Executive Summary ............................................................................................................... 14 Product Introduction ...................................................................................................... 14 Conclusions on the Substantial Evidence of Effectiveness ............................................ 14 Benefit-Risk Assessment ................................................................................................ 15 Patient Experience Data ................................................................................................. 19 2 Therapeutic Context .............................................................................................................. 20 Analysis of Condition ...................................................................................................... 20 Analysis of Current Treatment Options ......................................................................... 20 3 Regulatory Background ......................................................................................................... 21 U.S. Regulatory Actions and Marketing History ............................................................. 21 Summary of Presubmission/Submission Regulatory Activity ........................................ 21 4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ................................................................................................................. 24 Office of Scientific Investigations (OSI) .......................................................................... 24 Product Quality .............................................................................................................. 24 Clinical Microbiology ...................................................................................................... 24 Devices and Companion Diagnostic Issues .................................................................... 24 5 Nonclinical Pharmacology/Toxicology................................................................................... 25 Executive Summary ........................................................................................................ 25 Referenced NDAs, BLAs, DMFs ....................................................................................... 27 Pharmacology ................................................................................................................. 27 ADME/PK ........................................................................................................................ 29 Toxicology ....................................................................................................................... 36 General Toxicology .................................................................................................. 37 Genetic Toxicology .................................................................................................. 41 Carcinogenicity ........................................................................................................ 42 Reproductive and Developmental Toxicology ........................................................ 42 Other Toxicology Studies ........................................................................................ 49 6 Clinical Pharmacology ............................................................................................................ 51 2 Version date: July 7, 2019 Reference ID: 4754756 NDA/BLA Multi-disciplinary Review and Evaluation: NDA 212994 Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules, for oral use Executive Summary ........................................................................................................ 51 6.1.1 Recommendations ................................................................................................. 52 6.2 Summary of Clinical Pharmacology Assessment ............................................................ 53 6.2.1 Pharmacology and Clinical Pharmacokinetics ........................................................ 53 6.2.2 General Dosing and Therapeutic Individualization .................................................. 54 6.3 Comprehensive Clinical Pharmacology Review ............................................................. 55 6.3.1 General Pharmacology and Pharmacokinetic Characteristics ................................ 55 6.3.2 Clinical Pharmacology Questions ............................................................................ 57 7 Sources of Clinical Data and Review Strategy ....................................................................... 67 7.1 Table of Clinical Studies .................................................................................................. 67 Review Strategy ........................................................................................................................ 69 8 Statistical and Clinical Evaluation .......................................................................................... 69 8.1 Review of Relevant Individual Trials Used to Support Efficacy ...................................... 69 8.1.1 Study KP415.E01: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study with KP415 in Children with Attention-Deficit/Hyperactivity Disorder ................................................................. 69 8.1.2 Study Results ........................................................................................................... 73 8.1.3 Assessment of Efficacy Across Trials ....................................................................... 88 8.1.4 Integrated Assessment of Effectiveness ................................................................. 89 8.2 Review of Safety ............................................................................................................. 89 8.2.1 Safety Review Approach ......................................................................................... 89 8.2.2 Review of the Safety Database ............................................................................... 89 8.2.3 Adequacy of Applicant’s Clinical Safety Assessments ............................................ 90 8.2.4 Safety Results .......................................................................................................... 93 8.2.5 Analysis of Submission-Specific Safety Issues ....................................................... 108 8.2.6 Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability ...... 108 8.2.7 Safety Analyses by Demographic Subgroups ........................................................ 109 8.2.8 Specific Safety Studies/Clinical Trials .................................................................... 110 8.2.9 Additional Safety Explorations .............................................................................
Load more

Recommended publications
  • Drug Information Center Highlights of FDA Activities
    Drug Information Center Highlights of FDA Activities – 3/1/21 – 3/31/21 FDA Drug Safety Communications & Drug Information Updates: Ivermectin Should Not Be Used to Treat or Prevent COVID‐19: MedWatch Update 3/5/21 The FDA advised consumers against the use of ivermectin for the treatment or prevention of COVID‐19 following reports of patients requiring medical support and hospitalization after self‐medicating. Ivermectin has not been approved for this use and is not an anti‐viral drug. Health professionals are encouraged to report adverse events associated with ivermectin to MedWatch. COVID‐19 EUA FAERS Public Dashboard 3/15/21 The FDA launched an update to the FDA Adverse Event Reporting System (FAERS) Public Dashboard that provides weekly updates of adverse event reports submitted to FAERS for drugs and therapeutic biologics used under an Emergency Use Authorization (EUA) during the COVID‐19 public health emergency. Monoclonal Antibody Products for COVID‐19 – Fact Sheets Updated to Address Variants 3/18/21 The FDA authorized revised fact sheets for health care providers to include susceptibility of SARS‐CoV‐2 variants to each of the monoclonal antibody products available through EUA for the treatment of COVID‐19 (bamlanivimab, bamlanivimab and etesevimab, and casirivimab and imdevimab). Abuse and Misuse of the Nasal Decongestant Propylhexedrine Causes Serious Harm 3/25/21 The FDA warned that abuse and misuse of the nasal decongestant propylhexedrine, sold OTC in nasal decongestant inhalers, has been increasingly associated with cardiovascular and mental health problems. The FDA has recommended product design changes to support safe use, such as modifications to preclude tampering and limits on the content within the device.
    [Show full text]
  • Attention-Deficit Hyperactivity Disorder (ADHD) Stimulant Step Therapy
    Policy: Attention-Deficit Hyperactivity Disorder (ADHD) Annual Review Date: Stimulant Step Therapy Policy 03/18/2021 Last Revised Date: 06/17/2021 OVERVIEW All of the long-acting stimulants are indicated for the treatment of attention-deficit hyperactivity disorder (ADHD). Some products are also indicated for the treatment of narcolepsy. Vyvanse is the only stimulant medication indicated for the treatment of binge eating disorder (BED). Approval for this indication was based on two 12-week randomized, double- blind, multi-center, parallel-group, placebo-controlled, dose-optimization studies in adults aged 18 to 55 years (n = 374 and n = 350) with moderate to severe BED. Patients from both studies on Vyvanse had a statistically significantly greater reduction from baseline in mean number of binge days/week at Week 12. All of these products have abuse potential and are Schedule II controlled substances. POLICY STATEMENT A step therapy program has been developed to encourage use of one Preferred product prior to the use of a Non-Preferred product. If the step therapy rule is not met for a Non-Preferred agent at the point of service, coverage will be determined by the step therapy criteria below. All approvals are provided for 1 year in duration. Automation: Patients with a history of one Preferred drug within the 130-day look-back period are excluded from step therapy. Preferred Medications: • Generic amphetamine/dextroamphetamine extended-release capsules (generics to Adderall XR) • Generic dexmethylphenidate extended-release capsules (generics
    [Show full text]
  • PRODRUG TECHNOLOGY Prodrugs for ADHD Treatments: Opportunities &
    PRODRUG TECHNOLOGY Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs By: Travis Mickle, PhD INTRODUCTION one or more of the ADME categories — Absorption, Distribution, Metabolism, and Excretion — with the goal being the creation of Attention-deficit/hyperactivity disorder (ADHD) is a neuro- a new chemical entity (NCE) that optimizes the performance, util- logical disorder associated with an ongoing pattern of inattention, ity, and potential life-cycle management of the parent drug. hyperactivity, and/or impulsivity that may impede, for example, cognitive and social functioning, and as well as mental growth and development. Since 1937, more than 25 different products ADHD THERAPEUTIC MARKET have been approved by the FDA to treat ADHD. Despite the many pharmacological advances, there is still no optimal treatment of The Centers for Disease Control and Prevention noted in a this condition, leading prescribers and patients to press for im- 2016 report from the National Survey of Children’s Health that provements that address key shortcomings with currently available 6.1 million, or 9.4% of children aged 4 to 17, suffer from ADHD. ADHD medications. Duration of efficacy, consistency of drug ex- Yet, of all children 2 to 17 years of age that may qualify to take posure and effect, onset of action, and lower abuse potential are ADHD medication, only about 317,000 (or 1 in 20) are currently just some of the key attributes that new technologies are seeking being treated. Globally, there are a reported 175 million cases to address. of ADHD in people 5 to 44 years old, and the forecast indicates In the quest for the optimal ADHD medication, leading re- that this number will rise to more than 185 million by 2025.
    [Show full text]
  • Federal Register/Vol. 86, No. 87/Friday, May 7, 2021/Rules And
    Federal Register / Vol. 86, No. 87 / Friday, May 7, 2021 / Rules and Regulations 24487 that authority because it addresses an (1) With a switch unit serial number (S/N) Branch, send it to the attention of the person unsafe condition that is likely to exist or 1413, 1414, 1415, 1424, 1428, 1430, 1432, or identified in paragraph (i)(1) of this AD. develop on helicopters identified in this 1433 installed, or Information may be emailed to: 9-AVS-AIR- rulemaking action. (2) With a missing or illegible switch unit [email protected]. S/N or if the S/N cannot be determined, (2) Before using any approved AMOC, Regulatory Findings installed. notify your appropriate principal inspector, Note 1 to paragraph (c): Helicopters with or lacking a principal inspector, the manager This AD will not have federalism a 206L–1+ designation are Model 206L–1 of the local flight standards district office/ implications under Executive Order helicopters. Helicopters with a 206L–3+ certificate holding district office. 13132. This AD will not have a designation are Model 206L–3 helicopters. (i) Related Information substantial direct effect on the States, on Note 2 to paragraph (c): The switch unit the relationship between the national is located on the aft fuel boost pump (1) For more information about this AD, government and the States, or on the assembly. The P/N and S/N for the switch contact Hal Jensen, Aerospace Engineer, unit could be on the outside face of the Operational Safety Branch, FAA, 950 distribution of power and L’Enfant Plaza N SW, Washington, DC 20024; responsibilities among the various attachment flange, in the cross hatched area of the switch unit.
    [Show full text]
  • Carbon-I I-D-Threo-Methylphenidate Binding to Dopamine Transporter in Baboon Brain
    Carbon-i i-d-threo-Methylphenidate Binding to Dopamine Transporter in Baboon Brain Yu-Shin Ding, Joanna S. Fowler, Nora D. Volkow, Jean Logan, S. John Gatley and Yuichi Sugano Brookhaven National Laboratory, Upton, New York; and Department of Psychiatry, SUNY Stony Brook@Stony Brook@NY children (1). MP is also used to treat narcolepsy (2). The The more active d-enantiomer of methyiphenidate (dI-threo psychostimulant properties of MP have been linked to its methyl-2-phenyl-2-(2-piperidyl)acetate, Ritalin)was labeled with binding to a site on the dopamine transporter, resulting in lic (t1,@:20.4 mm) to characterize its binding, examine its spec inhibition of dopamine reuptake and enhanced levels of ificftyfor the dopamine transporter and evaluate it as a radio synaptic dopamine. tracer forthe presynapticdopaminergicneuron. Methods PET We have developed a rapid synthesis of [11C]dl-threo studies were canied out inthe baboon. The pharmacokinetics of methylphenidate ([“C]MP)to examine its pharmacokinet r1c]d-th@O-msth@ha@idate @f'1C]d-thmo-MP)weremeasured ics and pharmacological profile in vivo and to evaluate its and compared with r1cY-th@o-MP and with fts racemate ff@1C]fl-thmo-meth@1phenidate,r1c]MP). Nonradioact,ve meth suitability as a radiotracer for the presynaptic dopaminergic ylphenidate was used to assess the reveralbilityand saturability neuron (3,4). These first PET studies of MP in the baboon of the binding. GBR 12909, 3@3-(4-iodophenyI)tropane-2-car and human brain demonstrated the saturable [1‘C]MP boxylic acid methyl ester (fi-Cfl), tomoxetine and citalopram binding to the dopamine transporter in the baboon brain were used to assess the binding specificity.
    [Show full text]
  • Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb As an Allosteric Modulator of the Human Dopamine Transporter
    biomedicines Article Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter Shaili Aggarwal 1, Mary Hongying Cheng 2 , Joseph M. Salvino 3 , Ivet Bahar 2 and Ole Valente Mortensen 1,* 1 Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA; [email protected] 2 Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.H.C.); [email protected] (I.B.) 3 The Wistar Institute, Philadelphia, PA 19104, USA; [email protected] * Correspondence: [email protected] Abstract: The dopamine transporter (DAT) serves a critical role in controlling dopamine (DA)- mediated neurotransmission by regulating the clearance of DA from the synapse and extrasynaptic regions and thereby modulating DA action at postsynaptic DA receptors. Major drugs of abuse such as amphetamine and cocaine interact with DATs to alter their actions resulting in an enhancement in extracellular DA concentrations. We previously identified a novel allosteric site in the DAT and the related human serotonin transporter that lies outside the central orthosteric substrate- and cocaine-binding pocket. Here, we demonstrate that the dopaminergic psychostimulant sydnocarb is a ligand of this novel allosteric site. We identified the molecular determinants of the interaction between sydnocarb and DAT at the allosteric site using molecular dynamics simulations. Biochemical- Citation: Aggarwal, S.; Cheng, M.H.; Salvino, J.M.; Bahar, I.; Mortensen, substituted cysteine scanning accessibility experiments have supported the computational predictions O.V. Functional Characterization of by demonstrating the occurrence of specific interactions between sydnocarb and amino acids within the Dopaminergic Psychostimulant the allosteric site.
    [Show full text]
  • Psychiatric Medication Update Objectives Abbreviations
    3/30/2021 Psychiatric Medication Update Kara Gagnon, PharmD, BCPS, BCPP Pharmacy & Behavioral Health Programs Manager Objectives Identify newly approved psychiatric medications Discuss medications currently in the pipeline Review pertinent FDA MedWatch Alerts Evaluate new treatment guidelines for schizophrenia Abbreviations ADHD: Attention Deficit Hyperactivity Disorder AP: Antipsychotic CNS: Central Nervous System FDA: Food and Drug Administration FGA: First Generation Antipsychotic SGA: Second Generation Antipsychotic VMAT2: Vesicular monoamine transporter 2 1 3/30/2021 FDA Drug Approval Process ✓ Drug developed ✓ Animals tested ✓ Investigational New Drug (IND) application ✓ Phase 1 → Phase 2 → Phase 3 trials ✓ Review meeting: FDA + drug sponsor ✓ New Drug Application ✓ FDA NDA Review ✓ Drug Labeling ✓ Manufacturer facility inspection ✓ Drug Approval ✓ Post-Marketing monitoring Food and Drug Administration. Drug Approval Process. Accessed March 21, 2021. https://www.fda.gov/media/82381/download FDA Drug Approval Process Faster Approval Options ➢ Accelerated Approval ➢ Fast Track Prescription Drug User Fee Act (1992) FDA MedWatch ➢ Voluntary system for physicians and consumers to report adverse events Food and Drug Administration. Drug Approval Process. Accessed March 21, 2021. https://www.fda.gov/media/82381/download AzstarysTM (serdexmethylphenidate/dexmethylphenidate) FDA Approval: March 2, 2021 CNS stimulant for treatment of ADHD in patients 6 years of age and older Norepinephrine dopamine reuptake inhibitor; Schedule II substance KemPharm, Inc. ➢ LAT® (Ligand Activated Therapy) technology Azstarys. Package Insert. KemPharm Inc. 2021. 2 3/30/2021 AzstarysTM (serdexmethylphenidate/dexmethylphenidate) Novel once-daily oral capsule ➢ First and only product with dexmethylphenidate prodrug Three strengths available ➢ 26.1mg/5.2mg, 39.2mg/7.8mg, 52.3mg/10.4mg Warnings & Precautions ➢ Abuse/dependence, cardiovascular, psychiatric, growth suppression Azstarys.
    [Show full text]
  • (KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
    Kaiser Permanente Insurance Company (KPIC) PPO and Out-of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier This Drug Formulary was updated: September 1, 2021 NOTE: This drug formulary is updated often and is subject to change. Upon revision, all previous versions of the drug formulary are no longer in effect. This document contains information regarding the drugs that are covered when you participate in the California Nongrandfathered PPO and Out-of- Area Indemnity (OOA) Health Insurance Plans with specialty drug tier offered by Kaiser Permanente Insurance Company (KPIC) and fill your prescription at a MedImpact network pharmacy. Access to the most current version of the Formulary can be obtained by visiting kp.org/kpic-ca-rx-ppo-ngf. For help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit, please call 1-800-788-0710 or 711 (TTY) Monday through Friday, 7a.m. to 7p.m. For help with this Formulary, including the processes for submitting an exception request and requesting prior authorization and step therapy exceptions, please call MedImpact 24 hours a day, 7 days a week, at 1-800-788-2949 or 711 (TTY). For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit: kp.org/kpic-ca-rx-ppo-ngf. For help in your preferred language, please see the Kaiser Permanente Insurance Company Notice of Language Assistance in this document. KPIC PPO NGF Table of Contents Informational Section................................................................................................................................2
    [Show full text]
  • Attention Deficit Hyperactivity Disorder Stimulant Medications
    Cigna National Formulary Coverage Policy Step Therapy Attention Deficit Hyperactivity Disorder Stimulant Medications Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 14123 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 4 References .......................................................... 5 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • Psychiatric Medication Update
    Psychiatric Medication Update Jeffrey Bowers R.Ph., BCPP Clinical Psychiatric Pharmacist Cox North Hospital Pharmacy Springfield Missouri Objectives Discuss the meaning of New Medication Review new medications Learn to evaluate medications A New Medication for Weight Loss What does that mean? Obesity is now “cured”? For some patients, obesity is “cured”? https://contrave.com/about/ Usual dosage: Two tablets (naltrexone 16 mg/bupropion 180 mg) twice daily Contrave Contrave (bupropion/naltrexone) is a combination product used to promote and maintain weight loss in obese adults or overweight adults who have weight related medical problems. Contrave is the most popular opioid antagonist/atypical antidepressant combinations. There are currently no generic alternatives to Contrave. GoodRx: https://www.goodrx.com/contrave?dosage=8mg-90mg&form=tablet&label_override=Contrave&quantity=120&sort_type=popularity Pharmacology Demystified How does naltrexone work? New Drug? A New Drug Hits The Market The Drug Development Process Step 1: Discovery and Development Step 2: Preclinical Research Step 3: Clinical Research Step 4: FDA Drug Review Step 5: FDA Post-Market Drug Safety Monitoring https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring Phase 1 Trial Study Participants: 20 to 100 healthy volunteers or people with the disease/condition. Length of Study: Several months Purpose: Safety and dosage Gather information about how a drug interacts with the human body Researchers adjust dosing schemes
    [Show full text]
  • Antidepressant Potential of Nitrogen-Containing Heterocyclic Moieties: an Updated Review
    Review Article Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review Nadeem Siddiqui, Andalip, Sandhya Bawa, Ruhi Ali, Obaid Afzal, M. Jawaid Akhtar, Bishmillah Azad, Rajiv Kumar Department of ABSTRACT Pharmaceutical Chemistry, Depression is currently the fourth leading cause of disease or disability worldwide. Antidepressant is Faculty of Pharmacy, Jamia Hamdard approved for the treatment of major depression (including paediatric depression), obsessive-compulsive University, Hamdard disorder (in both adult and paediatric populations), bulimia nervosa, panic disorder and premenstrual Nagar, New Delhi - dysphoric disorder. Antidepressant is a psychiatric medication used to alleviate mood disorders, such as 110 062, India major depression and dysthymia and anxiety disorders such as social anxiety disorder. Many drugs produce an antidepressant effect, but restrictions on their use have caused controversy and off-label prescription a Address for correspondence: risk, despite claims of superior efficacy. Our current understanding of its pathogenesis is limited and existing Dr. Sandhya Bawa, E-mail: sandhyabawa761@ treatments are inadequate, providing relief to only a subset of people suffering from depression. Reviews of yahoo.com literature suggest that heterocyclic moieties and their derivatives has proven success in treating depression. Received : 08-02-11 Review completed : 15-02-11 Accepted : 17-02-11 KEY WORDS: Antidepressant, depression, heterocyclic epression is a chronic, recurring and potentially life- monoamine oxidase inhibitors (MAOIs, e.g. Nardil®) tricyclic D threatening illness that affects up to 20% of the population antidepressants (TCAs, e.g. Elavil). They increases the synaptic across the globe.[1] The etiology of the disease is suboptimal concentration of either two (5-HT and NE) or all three (5-HT, concentrations of the monoamine neurotransmitters serotonin NE and dopamine (DA)) neurotransmitters.
    [Show full text]